The cancellation or postponement of elective procedures, including breast augmentations and reconstructions, due to the COVID-19 pandemic will have a moderately negative impact on the US market for breast implants and reconstructive devices in the short term, compounding the recent market decline due to the association of BIA-ALCL with macrotextured silicone breast implants. However, the market will return to growth, supported by continued patient demand for augmentation and reconstruction procedures, innovative technologies that improve the ease of implant placement, and efforts by companies to address concerns regarding product safety.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for breast implants and reconstructive devices in the US across a 10-year period.
The COVID-19 pandemic will negatively affect the breast implant and reconstructive device market.
To what extent will COVID-19 impact the breast implant and reconstructive device market?
Which procedures will be impacted the most?
How quickly will procedure volumes rebound?
Subsequent to initial declines, the market for breast implants and reconstructive devices will grow over the forecast period.
What factors will support market recovery? Which factors will limit growth in this market beyond the impact of the pandemic?
What are the current trends in product innovation, and how strongly will they impact the market in the coming years?
This market has been negatively impacted by safety concerns, such as BIA-ALCL and the associated recall of textured breast implants.
How has BIA-ALCL affected the US breast implant and reconstructive device market?
How has the recall of textured breast implants impacted market growth?
What strategies are manufacturers pursuing to address these safety concerns?
- Breast Implants And Reconstructive Devices - Market Insights - United States
Author(s): Attusa Chikodi, MBA
Attusa Chikodi is a senior analyst on the Orthopedics, Dental, and Aesthetics Medtech Insights team at DRG (Part of Clarivate), focused on the breast implant and reconstructive device markets. Attusa holds an MBA in pharmaceutical management from Narsee Monjee Institute of Management Studies and a Bachelor's degree in Industrial Microbiology.